Followers | 29 |
Posts | 4738 |
Boards Moderated | 0 |
Alias Born | 12/27/2007 |
Tuesday, July 14, 2015 1:25:55 PM
Ingram Micro (IM, $24.68, Buy): Trimming estimates on consumer related weakness and somewhat softer trends from enterprise. We are tweaking our forward estimates lower on Ingram to account for somewhat lower-than-expected spending from consumer and certain enterprise customers as well as increase competitiveness in the channel.
? Our expectations. Based on our resellers survey, we believe the company is seeing seasonal to slightly below trends in N. America while Europe remains mixed. We believe pricing still remains somewhat competitive particularly for consumer related products. Looking beyond the June-Q, we expect Ingram to point to a seasonal start in N. America with puts and takes on Europe (in addition to FX). We do believe pricing will stabilize gradually on rebate resets and price hike (by OEMs) benefits. We expect margins to gradually expand on improved mix (higher mix of cloud and services) and benefit from its recently announced restructuring activities. We also expect to get an update on IM’s relationship with Verizon’s dealer networks business, which led to lower-than-expected sales and gross margin pressure in the Mar-Q.
? Our estimates. We are tweaking our June-Q revenue and EPS estimates from $10.90bn and $0.54 to $10.88bn and $0.53. For the Sep-Q, we are now modeling sales up ~5% q/q to $11.41bn with essentially flat gross margin. Our EPS estimate is at $0.64. We also note that the company recently closed the acquisition of Arabian Applied Technology, which is expected to add about $200mn annually. Our FY15 estimates go from $47.12bn and $2.76 to $46.86bn and $2.72.
? Our take: Even with our number cuts, the stock is inexpensive, trading at ~9x P/E, which is below its peers and its historical average. We believe the current valuation metrics do not give the company enough credit for volume leverage, cost reduction efforts and focus on higher margin businesses. We maintain our Buy rating.
? Our 12-month target price of $33 is based on roughly 10x our FY16 non- GAAP EPS estimate of $3.26. Risks to our target price include: potential market share losses in Europe due to the significant restructuring efforts; a renewed pricing war between Ingram and its competitors if end demand fizzles; issues with IM’s enterprise-resource-planning (ERP) IT integration plans (though we do not see heavy lifting for the next few quarters).
Recent ANY News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 09:00:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/14/2024 09:31:39 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 11:22:03 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/12/2024 11:18:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 02:54:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/29/2024 10:15:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/26/2024 09:19:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 01:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:30:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:42:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:06:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:03:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 11:58:51 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/05/2024 09:15:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:19:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 01:30:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/03/2024 09:07:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 11:01:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 11:01:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:44:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:43:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/05/2023 09:37:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 09:21:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 01:04:52 AM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/17/2023 10:59:03 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM